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OBJECTIVE — The purpose of this study was to test the hypothesis that any degree of
abnormal glucose homeostasis detected on antepartum screening for gestational diabetes mel-
litus (GDM) should be associated with an increased risk of postpartum pre-diabetes or diabetes.
RESEARCH DESIGN AND METHODS — In this prospective cohort study, 487
women underwent 1) antepartum GDM screening by a glucose challenge test (GCT) and a
diagnostic oral glucose tolerance test (OGTT) and 2) postpartum metabolic characterization by
OGTT at 3 months after delivery. Four baseline glucose tolerance groups were deﬁned on the
basis of the antepartum GCT/OGTT: 1) GDM (n  137); 2) gestational impaired glucose toler-
ance (GIGT) (n  91); 3) abnormal GCT with normal glucose tolerance on an OGTT (abnormal
GCTNGT)(n166);and4)normalGCTwithNGTonanOGTT(normalGCTNGT)(n93).
RESULTS — The prevalence of postpartum glucose intolerance (pre-diabetes or diabetes)
increased across the groups from normal GCT NGT (3.2%) to abnormal GCT NGT (10.2%) to
GIGT (16.5%) to GDM (32.8%) (Ptrend  0.0001). On logistic regression analysis, all three
categories of abnormal glucose homeostasis in pregnancy independently predicted postpartum
glucoseintolerance:abnormalGCTNGToddsratio(OR)3.6(95%CI1.01–12.9);GIGTOR5.7
(1.6–21.1); and GDM OR 14.3 (4.2–49.1). Furthermore, both in pregnancy and at 3 months
postpartum, insulin sensitivity (ISOGTT) and pancreatic -cell function (insulinogenic index/
homeostasis model assessment of insulin resistance) progressively decreased across the groups
from normal GCT NGT to abnormal GCT NGT to GIGT to GDM (all Ptrend  0.0001).
CONCLUSIONS — Any degree of abnormal glucose homeostasis in pregnancy indepen-
dently predicts an increased risk of glucose intolerance postpartum.
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T
he diagnosis of gestational diabetes
mellitus (GDM) identiﬁes a popula-
tion of young women who have a
very high risk of ultimately developing
type2diabetesintheyearsaftertheindex
pregnancy(1,2).Thisrelationshipreﬂects
the fact that both GDM and type 2 diabe-
tes share a similar pathophysiology, char-
acterized by two main metabolic defects:
1) target cell resistance to the activity of
insulin (insulin resistance) and 2) insufﬁ-
cientsecretionofinsulinbythepancreatic
-cells to compensate for this peripheral
tissue resistance (-cell dysfunction)
(1,3). Pregnancy is characterized by se-
vere, acquired insulin resistance that has
longbeenthoughttoprovideashort-term
challengetothe-cells,withGDMarising
in those women whose -cells are unable
to meet this challenge. It is now under-
stood, however, that the defect in -cell
compensation that characterizes GDM is
chronic (not acquired during pregnancy)
and therefore may underlie the high risk
of type 2 diabetes in women who have a
history of previous GDM (1,4).
Although controversy exists regard-
ingthespeciﬁcprotocolstoapply,screen-
ing for GDM by glucose tolerance testing
in pregnancy has become a standard ele-
mentofobstetricalcare(5).Withthistest-
ing, GDM is diagnosed on the basis of
blood glucose levels that exceed speciﬁc
glycemic thresholds. Affected women
identiﬁedinthiswayarethentreatedwith
dietary therapy or insulin to reduce glu-
cose levels in pregnancy and improve ob-
stetrical outcome (6). These patients are
also advised to undergo testing for type 2
diabetespostpartum(7).Itisimportantto
recognize, however, that glucose toler-
ance testing in pregnancy also identiﬁes
many women with glycemic responses
that exceed the normal range but that do
not meet the thresholds required for the
diagnosis of GDM. These women are not
typically treated in any way and are not
subject to any postpartum surveillance.
Indeed, little is known about their post-
partum risk of glucose intolerance or dia-
betes. Given that pregnancy provides a
physiologic test of the body’s glucoregu-
latory capacity, we hypothesized that any
abnormality on glucose tolerance testing
in pregnancy should reﬂect a degree of
underlying -cell dysfunction and hence
should predict an increased risk of post-
partum dysglycemia. In this context,
our objective in this study was to sys-
tematically evaluate glucose tolerance
and metabolic function at 3 months
postpartum in a well-characterized co-
hort of women representing a broad
spectrum of glucose homeostasis on
GDM screening in pregnancy.
RESEARCH DESIGN AND
METHODS— This analysis was con-
ducted in the context of an ongoing ob-
servational study of early events in the
natural history of type 2 diabetes, in
which a cohort of women recruited at the
time of antepartum GDM screening are
undergoing longitudinal metabolic charac-
terizationinpregnancyandthepostpartum
period.Standardobstetricalpracticeatour
institution involves universal screening
forGDMinallpregnantwomenat24–28
weeks of gestation by a glucose challenge
test (GCT), wherein plasma glucose con-
centration is measured 1 h after ingestion
of 50 g of glucose. If the plasma glucose
level is 7.8 mmol/l, the patient is re-
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ance test (OGTT).
In the current study, healthy preg-
nant women attending outpatient obstet-
rics clinics were recruited in the late
second trimester, either before or just af-
ter their screening 50-g GCT. Regardless
of the GCT result, all participants then
underwent a 3-h 100-g OGTT for as-
sessment of glucose tolerance status in
pregnancy. At 3 months postpartum,
participants returned for reassessment
by a 2-h 75-g OGTT. The study protocol
was approved by the Mount Sinai Hospi-
tal Research Ethics Board, and all partici-
pants gave written informed consent. The
current analysis was restricted to the ﬁrst
487 women who had completed both the
pregnancy OGTT and the 3-month post-
partum OGTT by September 2007, rep-
resenting 4 years of recruitment.
Baseline evaluation
On the morning of the OGTT in preg-
nancy, interviewer-administered question-
naireswerecompleted,andanthropometric
measurements of height and weight were
obtained using a medical scale. In con-
junction with the GCT, the OGTT strati-
ﬁed subjects into the following four
glucosetolerancegroupsinpregnancy:1)
GDM, as deﬁned by National Diabetes
DataGroup(NDDG)criteria(8)(requires
atleasttwoofthefollowingontheOGTT:
fasting glucose 5.8 mmol/l, 1-h blood
glucose10.6mmol/l,2-hbloodglucose
9.2 mmol/l, or 3-h blood glucose 8.1
mmol/l); 2) gestational impaired glucose
tolerance(GIGT),asdeﬁnedbymeeting
only one of the above NDDG criteria; 3)
abnormal GCT with normal glucose tol-
erance (NGT), as deﬁned by having an
abnormal 50-g GCT followed by NGT
on the OGTT (deﬁned by meeting none
of the NDDG criteria); and 4) normal
GCT NGT, as deﬁned by having a nor-
mal 50-g GCT followed by NGT on the
OGTT.
Postpartum evaluation
Participantsreturnedtotheclinicalinves-
tigation unit for a 2-h 75-g OGTT at 3
months postpartum. Interviewer-
administered questionnaires were com-
pleted, and a physical examination was
performed, including measurement of
blood pressure (measured twice 5 min
apart by automatic sphygmomanometer
[Dinamap Pro 100-400]), weight, and
waist circumference.
The 2-h 75-g OGTT characterized
postpartum glucose tolerance into one of
thefollowingﬁvecategoriesaspercurrent
Canadian Diabetes Association clinical
practice guidelines (9): 1) diabetes, de-
ﬁned by fasting glucose 7.0 mmol/l or
2-h glucose 11.1 mmol/l; 2) impaired
glucose tolerance (IGT), deﬁned by fast-
ing glucose 6.1 mmol/l and 2-h glucose
between 7.8 and 11.0 mmol/l inclusive;
3)impairedfastingglucose(IFG),deﬁned
by fasting glucose between 6.1 and 6.9
mmol/l inclusive, with 2-h glucose 7.8
mmol/l; 4) combined IFG/IGT, deﬁned
by fasting glucose between 6.1 and 6.9
mmol/l inclusive, and 2-h glucose be-
tween 7.8 and 11.0 mmol/l inclusive; and
5) NGT, deﬁned by fasting glucose 6.1
mmol/l and 2-h glucose 7.8 mmol/l.
Pre-diabetes collectively refers to
IGT, IFG, and combined IFG/IGT (9).
Postpartum glucose intolerance collec-
tively refers to pre-diabetes and diabetes.
Laboratory measurements and
physiologic indexes
All OGTTs were performed in the morn-
ing after an overnight fast. During all
OGTTs, venous blood samples were
drawn for measurement of glucose and
insulin at fasting and at 30-, 60- and 120-
min after ingestion of the glucose load.
The 3-h OGTT in pregnancy involved an
additional venous blood sample at 180
min. Speciﬁc insulin was measured using
theRocheElecsys1010immunoassayan-
alyzer and the electrochemiluminescence
immunoassay kit. This assay shows
0.05% cross-reactivity to intact human
proinsulin and the primary circulating
split form (des 31,32).
At both baseline and follow-up, glyce-
mia was assessed by 1) glucose tolerance
status, as described above and 2) the total
areaundertheglucosecurve(AUCgluc)dur-
ing the OGTT, calculated using the trap-
ezoidal rule. Insulin sensitivity was
measured using the insulin sensitivity in-
dex (ISOGTT) of Matsuda and DeFronzo
(10,11). -Cell function was assessed by
the insulinogenic index (12) divided by
the homeostasis model assessment of in-
sulin resistance (HOMA-IR) (3,13).
HOMA-IR was calculated as described by
Matthews et al. (14).
Statistical analyses
All analyses were conducted using SAS
statisticalsoftware(version9.1;SASInsti-
tute, Cary, NC). Continuous variables
were tested for normality of distribution,
and natural log transformations of
skewedvariableswereused,whereneces-
sary, in subsequent analyses. Univariate
differences across the four study groups
were assessed in pregnancy (Table 1) and
at 3 months postpartum (Table 2; Fig. 1)
using one-way ANOVA for continuous
variables and either a 
2 test or Fisher’s
exact test for categorical variables. Uni-
variate correlations between continuous
variables in pregnancy and AUCgluc at 3
months postpartum were assessed by
Spearman correlation analysis. Multiple
linear regression analysis was used to de-
termine which factors in pregnancy were
independently associated with logarith-
mically transformed AUCgluc at 3 months
postpartum (panel A of the supplemental
Table available in an online appendix at
http://dx.doi.org/10.2337/dc08-0972).
Multivariate logistic regression analysis
was performed to determine which preg-
nancy factors were independently associ-
ated with glucose intolerance at 3 months
postpartum (panel B of the supplemental
Table).Thecovariatesconsideredinthese
analyses were those that were either re-
lated to postpartum glycemia on univari-
ate analysis at a signiﬁcance level of 0.05
or are known/suspected risk factors. The
same covariates were tested in both anal-
yses, with the exception of the categorical
variable previous GDM, which could not
beincludedinthelogisticregressionanal-
ysis because there were no women in the
normal GCT NGT group with a history of
previous GDM (i.e., inclusion of this co-
variatewouldthereforeunderminemodel
stability).
RESULTS
Baseline characteristics of study
groups in pregnancy
Table 1 shows the baseline characteristics
of the study participants, consisting of 93
women in the normal GCT NGT group,
166 in the abnormal GCT NGT group, 91
in the GIGT group (of whom 19 had a
normal GCT), and 137 with GDM (of
whom 17 had a normal GCT). As ex-
pected, mean AUCgluc showed a progres-
sive increase from normal GCT NGT
(19.6) to abnormal GCT NGT (21.0) to
GIGT (24.3) to GDM (27.7) (P 
0.0001). Furthermore, both insulin resis-
tance and -cell dysfunction followed the
same pattern, with ISOGTT (insulin sensi-
tivity)andinsulinogenicindex/HOMA-IR
(-cell function) both progressively de-
creasing across these four groups (both
P  0.0001).
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Having established that the GCT/OGTT
identiﬁes four metabolically distinct glu-
cose tolerance groups in pregnancy, we
next compared the metabolic characteris-
tics of these groups at 3 months postpar-
tum (Table 2). Importantly, the four
groups continued to exhibit marked met-
abolic differences at 3 months postpar-
tum. Speciﬁcally, as in pregnancy, both
insulin sensitivity (ISOGTT) and -cell
function(insulinogenicindex/HOMA-IR)
progressively decreased from the normal
GCT NGT group to the abnormal GCT
NGT group to the GIGT group to the
women with recent GDM (both P 
0.0001). Consistent with these differ-
ences, glycemia, as measured by AUCgluc
on the 3-month postpartum OGTT, in-
creased signiﬁcantly across these four
Table 1—Baseline demographic, clinical, and metabolic parameters of study subjects stratiﬁed by glucose tolerance status in pregnancy
Demographic and clinical features
Normal GCT
NGT
Abnormal GCT
NGT GIGT GDM P value
n 93 166 91 137
Age (years) 34.0  4.4 33.8  4.2 34.2  4.2 34.5  4.3 0.5917
Weeks of gestation 32 (30.5–34) 29 (28–30) 29 (28–31) 29 (28–31) 0.0001
Ethnicity: 0.0708
White 74 (79.6) 132 (79.5) 65 (71.4) 98 (71.5)
Asian 7 (7.5) 15 (9.0) 18 (19.8) 15 (11.0)
Other 12 (12.9) 19 (11.5) 8 (8.8) 24 (17.5)
Family history of diabetes 39 (41.9) 84 (50.6) 48 (52.8) 81 (59.1) 0.0120
Parity: 0.7087
Nulliparous 57 (61.3) 83 (50.0) 51 (56.0) 75 (54.7)
1 31 (33.3) 61 (36.8) 27 (29.7) 51 (37.2)
1 5 (5.4) 22 (13.3) 13 (14.3) 11 (8.0)
Previous GDM/macrosomic infant 0 (0) 6 (3.6) 11 (12.1) 10 (7.3) 0.0040
Prepregnancy BMI (kg/m
2) 23.0 (21.5–26.1) 23.5 (21.1–27.5) 23.5 (21.8–27.7) 25.0 (22.0–30.1) 0.0246
Weight gain in pregnancy up to
OGTT (kg) 12.8 (10.4–16.3) 10.0 (7.5–13.6) 10.0 (7.3–14.5) 9.1 (5.9–12.7) 0.0001
Smoking exposure: 0.2750
Never 58 (62.4) 114 (68.7) 66 (72.5) 103 (75.2)
Remote 34 (36.6) 51 (30.7) 23 (25.3) 32 (23.4)
Current 1 (1.1) 1 (0.6) 2 (2.2) 2 (1.5)
Glucose metabolism
GCT (mmol/l) 5.7 (5.2–6.6) 8.4 (8.0–9.1) 8.5 (7.9–9.0) 8.8 (8.2–9.5) 0.0001
Fasting glucose (mmol/l) 4.2 (4.0–4.5) 4.4 (4.2–4.6) 4.7 (4.3–5.0) 4.6 (4.3–5.2) 0.0001
AUCgluc 19.6  2.0 21.0  2.3 24.3  1.7 27.7  2.2 0.0001
ISOGTT 5.4 (3.7–7.3) 5.4 (3.6–7.3) 3.5 (2.7–5.0) 3.1 (2.2–5.0) 0.0001
Insulinogenic index/HOMA-IR 13.9 (9.7–19.6) 12.8 (8.6–18.1) 8.1 (4.6–10.8) 6.2 (3.5–10.3) 0.0001
Data are means  SD, medians (interquartile range), or n (%). P values refer to overall differences across groups as derived from ANOVA for continuous variables
(parametric test for normally distributed variables and nonparametric test for skewed variables) or a 
2 test for categorical variables (with the exception of smoking
exposure,forwhichFisher’sexacttestMehta’sextensionwasused).Familyhistoryofdiabetesreferstoahistoryoftype2diabetesinanyextendedfamilymember.
Table 2—Clinical and metabolic parameters at 3 months postpartum in study subjects stratiﬁed by glucose tolerance status in pregnancy
Normal GCT
NGT
Abnormal GCT
NGT GIGT GDM P value
n 93 166 91 137
Months postpartum 3.2 (2.9–3.6) 3.3 (2.9–4.1) 3.3 (3.0–3.7) 3.1 (2.9–3.5) 0.0875
BMI (kg/m
2) 24.6 (22.6–27.9) 25.8 (23.4–29.8) 26.0 (23.2–30.1) 26.6 (23.7–31.1) 0.0968
Waist circumference (cm) 86.0 (79.8–94.0) 85.2 (80–94) 87.0 (83–96) 88.6 (81–99) 0.0456
Systolic blood pressure (mmHg) 107.8 (100.8–113.5) 108.8 (102.5–114.0) 110.0 (103.5–115.5) 111.0 (105.0–119.5) 0.0286
Diastolic blood pressure (mmHg) 67.0 (60.0–70.0) 64.0 (59.5–70.0) 64.0 (60.0–70.0) 65.5 (60.0–73.0) 0.4467
Current smoking 4 (4.4) 6 (3.6) 4 (4.4) 6 (4.4) 0.9662
Current breast-feeding 88 (94.6) 153 (92.2) 80 (87.9) 131 (95.6) 0.8036
ISOGTT 11.3 (8.2–15.7) 9.4 (6.5–14.3) 8.1 (5.4–11.9) 8.0 (5.3–11.6) 0.0001
Insulinogenic index/HOMA-IR 14.1 (9.6–20.0) 9.8 (7.1–14.9) 8.9 (5.2–12.4) 8.1 (4.4–12.3) 0.0001
AUCgluc 18.0 (15.9–20.3) 19.8 (17.3–21.9) 21.1 (18.9–23.4) 22.7 (20.1–25.1) 0.0001
Data are medians (interquartile range) or n (%). P values refer to overall differences across groups as derived from ANOVA for continuous variables (parametric test
for normally distributed variables and nonparametric test for skewed variables), 
2 test for breast-feeding, or Fisher’s exact test for smoking.
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these metabolic differences between the
groups translated into vastly different
rates of glucose intolerance (i.e., pre-
diabetesordiabetes)at3monthspostpar-
tum (Fig. 1). Indeed, the prevalence of
glucose intolerance rose in a stepwise
fashion from 3.2% in the normal GCT
NGT group to 10.2% in the abnormal
GCT NGT group to 16.5% in the GIGT
groupto32.8%intheGDMgroup(Coch-
ran-Armitage Ptrend  0.0001). Further-
more, in each group, the bulk of this
dysglycemia was IGT (i.e., IGT preva-
lence rates per group were 2.2% for nor-
mal GCT NGT, 10.2% for abnormal GCT
NGT, 11.0% for GIGT, and 27.0% for
GDM), underscoring the importance of
the OGTT for its detection.
Determinants of postpartum glucose
intolerance
Having identiﬁed high rates of postpar-
tum glucose intolerance within each cat-
egory of abnormal antepartum glucose
homeostasis, we next sought to identify
the antepartum factors that predict dysg-
lycemia at 3 months postpartum. On
Spearman univariate correlation analysis,
the pregnancy factors that were most
strongly associated with postpartum
AUCgluc were measures of glycemia, in-
cluding AUCgluc in pregnancy (r  0.43,
P  0.0001), GCT result (r  0.36, P 
0.0001), and fasting glucose (r  0.26,
P  0.0001). Other signiﬁcant correlates
of postpartum AUCgluc were prepreg-
nancy BMI (r  0.17, P  0.0002) and
age (r  0.13, P  0.0043).
Onmultiplelinearregressionanalysis
(panel A of the supplemental Table), all
three categories of abnormal glucose ho-
meostasis in pregnancy were indepen-
dentlyassociatedwithdependentvariable
log AUCgluc at 3 months postpartum
(GDM t  8.00, P  0.0001; GIGT t 
5.43, P  0.0001; abnormal GCT NGT
t  3.03, P  0.0026). Other signiﬁcant
covariateswereage(t3.00,P0.0028),
nonwhite ethnicity (Asian t  2.77, P 
0.0059; other ethnicity t  2.22, P 
0.027), prepregnancy BMI (t  2.47,
P  0.0141), and previous GDM (t 
2.37, P  0.0181).
Finally, logistic regression analysis
(panel B of the supplemental Table) was
performed to identify the pregnancy fac-
tors that independently predict glucose
intolerance at 3 months postpartum. As
expected, GDM was an independent pre-
dictor(oddsratio[OR]14.3,95%CI4.2–
49.1). Importantly, however, both of the
other two categories of abnormal glucose
homeostasis in pregnancy were also sig-
niﬁcant independent predictors of post-
partum glucose intolerance with OR 5.7
(1.6–21.1) for GIGT and 3.6 (1.01–12.9)
for abnormal GCT NGT.
CONCLUSIONS— Inthisreport,we
demonstrate that standard antepartum
screening for GDM identiﬁes four meta-
bolicallydistinctglucosetolerancegroups
in pregnancy whose differences in insulin
sensitivity, -cell function, and glucose
handling persist at 3 months postpartum.
Indeed, the prevalence of postpartum
glucose intolerance progressively in-
creasesacrossthesefourgroups.Mostim-
portantly,anydegreeofabnormalglucose
homeostasis in pregnancy (i.e., not just
GDM)independentlypredictsglucosein-
tolerance at 3 months postpartum. Thus,
antepartum GDM screening provides an
opportunitytoobtaininsightintoawom-
en’s future risk of pre-diabetes and type 2
diabetes.
Women with GDM, who have
chronic insulin resistance and a chronic
defectintheirinsulinsecretion-sensitivity
relationship, are identiﬁed on the basis of
hyperglycemia on glucose tolerance test-
ing in pregnancy. The current data dem-
onstrate that standard GDM screening
can actually identify four distinct groups
with differences in insulin sensitivity,
-cell function, and glycemia in preg-
nancy. Speciﬁcally, compared with nor-
mal GCT NGT, GDM and GIGT were
associated with lower insulin sensitivity,
poorer -cell function, and greater glyce-
mia. In addition, abnormal GCT NGT was
associated with greater glycemia (AUCgluc)
than normal GCT NGT, although signiﬁ-
cant differences in insulin sensitivity and
-cell function were not detected with the
measures used in this study.
The signiﬁcance of this readily
achievable identiﬁcation of these four
groups (through standard clinical care
with GCT and OGTT) becomes apparent
when one considers that the metabolic
differences between these groups persist
into the postpartum period. Importantly,
the current data demonstrate that even
mild glucose intolerance in pregnancy
portends an increased risk of glucose in-
tolerance postpartum. In particular,
women with GIGT are clearly distinct
fromthosewithnormalGCTNGT,onthe
basis of lower insulin sensitivity, poorer
-cell function, and greater glycemia.
Furthermore, as in pregnancy, the abnor-
mal GCT NGT group exhibited greater
glycemia (AUCgluc) than the normal GCT
NGT group, with no detectable dissimi-
larity in -cell function, suggestive of a
persistent difference in glucoregulation
between these groups (the pathophysio-
logic basis of which remains unclear). In-
deed, the abnormal GCT NGT and GIGT
groups exhibited surprisingly high rates
ofpre-diabetes/diabetesat3monthspost-
partum (10.2 and 16.5%, respectively).
This relationship has escaped clinical at-
tention to date because it is driven largely
by the high prevalence of IGT in these
groups.Assuch,intheabsenceofsystem-
atic evaluation of postpartum glucose in-
tolerance by OGTT, as in this study, the
high rates of pre-diabetes would not be
detected.
The identiﬁcation of pre-diabetes is
important because up to 70% of affected
Figure 1— Prevalence of glucose intolerance (pre-diabetes or diabetes) at 3 months postpartum
per glucose tolerance group in pregnancy (Cochran-Armitage Ptrend  0.0001).
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2 diabetes (15). Thus, the high rates of
pre-diabetes in the three categories of ab-
normal antepartum glucose homeostasis
suggest that the young women in these
groups have an increased risk of future
type 2 diabetes. Although this risk is well
established for women with GDM (2,16–
19), there has been limited study of this
issueinwomenwithlesserdegreesofglu-
cose intolerance in pregnancy. Recently,
Vambergue et al. (20) reported that GIGT
was independently associated with glu-
cose intolerance at 6.75 years postpar-
tum,withanadjustedORof4.57(95%CI
1.47–14.22), which was similar to that
reported herein. Furthermore, based on
administrative data, Carr et al. (21) re-
centlyreportedthatwomenwithahistory
of GIGT have an increased risk of devel-
oping diabetes. Importantly, the current
study extends these ﬁndings by 1) careful
stratiﬁcation of subjects into four glucose
tolerancegroupsinpregnancy(withGCT
andOGTTinallsubjects),2)useofapro-
spective study design with ascertainment
of postpartum glucose tolerance status by
OGTT in all subjects, 3) the demonstra-
tion of signiﬁcant differences in insulin
sensitivity and -cell function between
thegroups,and4)thedemonstrationthat
even abnormal GCT NGT (i.e., a milder
abnormality than GIGT) independently
predicts postpartum glucose intolerance.
The signiﬁcance of our study rests in
its illustration of the concept that the
spectrum of abnormal glucose homeosta-
sisinpregnancyidentiﬁesacontinuumof
risk for postpartum glucose intolerance
andthatthisspectrumextendstolevelsof
antepartum dysglycemia far less severe
than GDM. Interestingly, our demonstra-
tion that, compared with their truly nor-
malpeerswithnormalGCTNGT,women
with GIGT and even those with abnormal
GCT NGT have metabolic perturbations
that translate into an increased risk of
postpartum glucose intolerance is consis-
tent with an emerging body of literature
indicating that these two groups (like
women with GDM) have an enhanced
risk of adverse obstetrical outcomes (22–
27).Theseobstetricaldatahaveposedthe
question as to whether glucose-lowering
treatment in pregnancy, as prescribed for
GDM, should be instituted for these
groups of women. In the same way, the
currentdataraisethepossibilitythatpost-
partum follow-up for diabetes surveil-
lance (as is currently recommended after
GDM) should be considered for women
withGIGTandpossiblythosewithabnor-
mal GCT NGT. The importance of this
question is underscored by the fact that
the population in question is young
women of child-bearing age, in whom
early detection and/or prevention of dia-
betes could have enormous public health
implications. Further long-term fol-
low-up will be needed, with a particular
emphasisonthecost-beneﬁtimplications
of any postpartum screening strategies
under consideration.
A limitation of the current study is
that the CIs surrounding the adjusted
ORs in the logistic regression analysis of
postpartum glucose intolerance are rela-
tively wide, probably reﬂecting limita-
tionsinpower.Nevertheless,ourﬁndings
are supported by the complete consis-
tencyoftheassociationsbetweeneachab-
normal glucose tolerance group in
pregnancy and 1) postpartum glycemia
(both glucose intolerance and AUCgluc),
2) insulin resistance, and 3) -cell dys-
function. Furthermore, although the
other independent determinants of post-
partum AUCgluc did not persist as signif-
icant predictors of the categorical
outcome of postpartum glucose intoler-
ance, it should be noted that the three ab-
normal glucose tolerance groups in
pregnancy were the only signiﬁcant inde-
pendent predictors of both the continuous
and the categorical measure of postpartum
glycemia (supplemental Table). A second
limitation is that this analysis was per-
formed in the ﬁrst 487 women who re-
turned for their study visit at 3 months
postpartum, representing nearly 70% re-
tention of the originally recruited cohort.
Although we cannot fully exclude the pos-
sibility that loss-to-follow-up may have bi-
ased the study groups in some way, it is
encouraging that the women who did not
return were similar to the participants who
didreturnwithrespecttodemographicand
clinical features, including ethnicity, family
history of diabetes, and BMI at 3 months
(determined from weight reported on tele-
phonequestionnairefollow-upwithnonre-
turners). Furthermore, the retention of a
large number of subjects within each of the
four baseline glucose tolerance groups also
supports the relevance of this analysis.
In summary, standard antepartum
screening for GDM identiﬁes four meta-
bolicallydistinctglucosetolerancegroups
in pregnancy, whose differences in insu-
lin sensitivity, -cell function, and glu-
cose tolerance persist at 3 months
postpartum. Importantly, any degree of
abnormal glucose homeostasis in preg-
nancy (i.e., not just GDM) independently
predicts glucose intolerance at 3 months
postpartum. Thus, clinical screening for
GDM, as currently practiced, provides an
opportunitytoobtaininsightintoawom-
an’s future risk of pre-diabetes and type 2
diabetes, information that may have im-
plications for diabetes surveillance and
prevention.
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